Vera Therapeutics, Inc.

VERA

Vera Therapeutics, Inc.

VERA

Insider Sentiment (TTM):

Last Purchase:2025-12-11Last Sale:2026-06-23Shares Purchased (TTM):5,882Shares Sold (TTM):142,305

Institutional Sentiment:

As of:2026-03-31Institutional Shares Owned:67,429,968Shares Outstanding:71,476,595Institutional Ownership Pct.:94.34%

Earnings Market Reaction:

Filing Date:2026-08-10Price on Filing Date:N/APrevious Close:N/A% Change:N/A

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Financial Statements

10‑Q10‑K

Values in Millions ($)	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30
Assets
Assets Current
Cash And Cash Equivalents At Carrying Value	49	114	355	58	49	55	93	27	25	69	46	27
Marketable Securities Current	450	482	360	440	508	535	548	326	359	335	115	132
Prepaid Expense And Other Assets Current	28	19	14	14	15	16	10	11	10	13	11	12
Assets Current	527	616	729	511	571	606	651	364	395	416	172	172
Restricted Cash Noncurrent	-	-	-	-	-	-	-	-	-	-	0	0
Other Assets Noncurrent	5	6	-	-	-	-	-	-	-	-	-	-
Property Plant And Equipment Net	-	1	1	1	1	1	1	0	0	0	0	0
Assets	533	622	735	518	579	610	656	369	397	419	176	176
Operating Lease Right Of Use Asset	-	2	2	2	2	3	3	4	2	2	3	3
Prepaid Expense And Other Assets Noncurrent	-	-	3	3	4	0	0	0	0	0	0	0
Liabilities And Stockhold…
Marketable Securities Noncurrent	-	-	-	-	-	-	-	-	-	-	0	0
Liabilities Current
Accounts Payable Current	15	14	22	18	13	9	8	5	5	5	11	12
Operating Lease Liability Current	-	-	1	0	1	1	1	2	2	2	2	3
Accrued Liabilities Current	34	31	31	23	20	11	16	20	12	7	9	10
Liabilities Current	48	45	53	42	34	22	25	26	18	15	22	25
Long Term Debt	75	75	75	75	74	51	51	50	50	50	50	25
Operating Lease Liability Noncurrent	-	-	2	2	2	2	2	3	0	1	1	2
Other Liabilities Noncurrent	2	2	-	-	-	-	-	-	-	-	-	-
Liabilities	125	122	130	119	110	75	79	80	69	66	74	52
Stockholders Equity
Preferred Stock Value	-	-	-	0	0	0	0	0	0	0	0	0
Common Stock Value	0	0	0	0	0	0	0	0	0	0	0	-
Additional Paid In Capital Common Stock	1,399	1,382	1,365	1,068	1,057	1,047	1,038	706	699	691	410	407
Accumulated Other Comprehensive Income Loss Net Of…	-0	-0	1	1	1	1	0	1	-0	-0	0	-0
Retained Earnings Accumulated Deficit	-991	-882	-761	-670	-589	-513	-461	-418	-371	-337	-309	-283
Stockholders Equity	408	500	605	399	468	535	577	289	328	354	102	124
Liabilities And Stockholders Equity	533	622	735	518	579	610	656	369	397	419	176	176
Preferred Stock Par Or Stated Value Per Share	0.001	0.001	0	0.001	0.001	0.001	0	0.001	0.001	0.001	0	0.001
Preferred Stock Shares Authorized	-	10	10	10	10	10	10	10	10	10	10	10
Preferred Stock Shares Issued	-	-	-	0	0	0	0	0	0	0	0	0
Preferred Stock Shares Outstanding	-	-	-	0	0	0	0	0	0	0	0	0

Subscribe to unlock 17+ years of financial data, unlimited metrics, and saved tables

Start 7-day free trial

Subscribe to unlock 17+ years of data, unlimited metrics, and saved tables

Start free trial

Custom Table

10‑Q10‑K

0/5

Search a metric to start building a table

Subscribe to unlock 17+ years of financial data, unlimited metrics, transformations, and saved visuals

Start 7-day free trial

Subscribe to unlock 17+ years of data, unlimited metrics, transformations, and saved visuals

Start free trial

Interactive Financial Visualizations

10‑Q10‑K

Stock Price:

OnOff

Transformations:

0/1

Search a metric to start building a visual

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Earnings Market Reaction

10‑Q10‑K

Fiscal Year	Q1 1 Month	Q1 2 Month	Q1 3 Month	Q2 1 Month	Q2 2 Month	Q2 3 Month	Q3 1 Month	Q3 2 Month	Q3 3 Month	Q4 1 Month	Q4 2 Month	Q4 3 Month
2026	-1.00%	18.34%	-1.20%	-	-	-	-	-	-	-	-	-
2025	-16.22%	0.13%	-3.58%	4.84%	36.63%	41.57%	40.04%	122.32%	97.05%	-4.30%	-0.12%	-11.88%
2024	-8.06%	-12.44%	-11.18%	5.50%	21.17%	14.62%	1.45%	-15.56%	-30.83%	-9.52%	-28.87%	-29.00%
2023	-	-	-	-	-	-	20.24%	33.62%	162.21%	-13.30%	-5.57%	-17.82%
Earnings Market Reaction data beyond 3 years is for subscribers only. Unlock the full earnings market reaction history Start 7-day free trial

Subscribe to unlock 17+ years of financial data and 90+ calculated metrics

Start 7-day free trial

Subscribe to unlock 17+ years of data and 90+ calculated metrics

Start free trial

Performance and Valuation Metrics

Rows marked with a lock icon are subscribers only — subscribe to unlock 90+ calculated metrics and 17+ years of history.

Metrics	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30
Liquidity Ratios
Current Ratio	10.92	13.64	13.64	12.21	17.03	27.68	25.67	13.76	21.43	28.63	7.71	6.97
Quick Ratio	10.33	13.22	13.37	11.88	16.59	26.94	25.26	13.35	20.87	27.76	7.21	6.50
Working Capital	479.17M	570.65M	675.43M	469.43M	537.80M	584.18M	625.85M	337.67M	376.33M	401.83M	149.72M	147.00M
Leverage & Debt
Debt to Equity	0.31	0.24	0.22	0.30	0.24	0.14	0.14	0.28	0.21	0.19	0.73	0.42
Interest Coverage TTM	-55.17	-50.70	-41.89	-36.03	-31.58	-25.73	-21.92	-21.34	-20.16	-21.14	-26.94	-32.60
Debt Ratio	0.23	0.20	0.18	0.23	0.19	0.12	0.12	0.22	0.17	0.16	0.42	0.30
Efficiency & Turnover
Asset Turnover TTM	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Per Share Metrics
Diluted EPS TTM	-5.59	-5.16	-4.66	-3.95	-3.42	-2.76	-2.75	-2.45	-1.97	-1.85	-2.25	-2.32
Free Cash Flow Per Share TTM	-4.00	-4.11	-3.76	-2.46	-2.07	-2.46	-2.45	-2.20	-1.95	-1.96	-2.16	-1.99
Dividend Per Share TTM	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Growth Metrics
Net Income Growth (1Y)	84.12%	110.28%	96.92%	87.49%	102.39%	86.06%	58.50%	30.75%	0.47%	-7.58%	7.79%	39.90%
EPS Growth (1Y)	63.49%	87.32%	69.62%	61.21%	73.65%	48.95%	22.35%	5.66%	-18.73%	-31.70%	-32.94%	-14.18%
Valuation Metrics
P/E TTM	-7.67	-7.79	-10.86	-7.36	-6.89	-8.72	-15.38	-18.06	-18.36	-23.31	-6.84	-5.92
P/B TTM	7.56	5.75	5.38	4.65	3.21	2.86	4.05	8.39	6.04	6.22	6.46	4.92
Market Cap	3.08B	2.88B	3.25B	1.86B	1.50B	1.53B	2.34B	2.43B	1.98B	2.20B	656.83M	608.22M
Enterprise Value	3.11B	2.84B	3.13B	1.87B	1.53B	1.53B	2.30B	2.45B	2.01B	2.18B	661.03M	605.82M
Calculated Values
Free Cash Flow TTM	-287.03M	-293.66M	-241.73M	-156.87M	-131.96M	-156.41M	-135.65M	-121.03M	-106.88M	-99.78M	-92.24M	-88.20M
Net Debt	26.35M	-39.32M	-117.90M	16.88M	25.34M	-4.18M	-41.96M	23.21M	25.18M	-19.04M	4.20M	-2.40M
Per-Share and Margin
EPS TTM
Adjusted EPS TTM
Cash Flow Per Share TTM
Pretax Margin TTM
Stock Comp to Revenue TTM
Turnover Ratios and Averages
Average Assets
Average Equity
Average Inventory
Average Receivables
Average Accounts Payables
Inventory Turnover TTM
Payables Turnover TTM
Days Inventory Outstanding TTM
Days Payables Outstanding TTM
Cash Conversion Cycle TTM
Working Capital to Revenue
Deferred Revenue to Revenue
Growth Rates
Total Assets Growth (1Y)
Total Assets Growth (3Y)
Total Assets Growth (5Y)
Dividends Paid Growth (1Y)
Dividends Paid Growth (3Y)
Dividends Paid Growth (5Y)
EPS Growth (3Y)
EPS Growth (5Y)
Net Income Growth (3Y)
Net Income Growth (5Y)
Net Profit Margin Growth (1Y)
Net Profit Margin Growth (3Y)
Net Profit Margin Growth (5Y)
Net Revenue Growth (3Y)
Net Revenue Growth (5Y)
Deferred Revenue Growth (1Y)
Retained Earnings Growth (1Y)
Credit, Liquidity, Returns, Payout
Cash Ratio
Net Working Capital
Debt to EBITDA TTM
Net Debt to EBITDA TTM
Net Debt to Equity
Altman A
Altman B
Altman C
Altman D
Altman E
Altman Z-Score
ROA TTM
ROE TTM
NOPAT TTM
ROIC TTM
Effective Tax Rate TTM
Payout Ratio TTM
Dilution Ratio
Retained Earnings to Equity
Treasury Stock to Equity
Treasury Stock Change (1Y)
Accrued to Current Liabilities
NCAV
NCAV Per Share TTM
Valuation Ratios
P/CF TTM
PEG Ratio
Dividend Yield TTM
Free Cash Flow Yield TTM
EV EBITDA TTM
EV EBIT TTM
EV Revenue TTM
EV FCF TTM
Stock Compensation TTM
Adjusted Net Income TTM
Billings TTM
Total Debt
Invested Capital

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Insider Transactions

2026-06-23Sale

Owner: Fordyce, Marshall

Title: PRESIDENT AND CEO

Shares: 18,500

Price/Share: $38.18

Value: $706,330.00

Shares Owned: 198,244

Relationship: Director,Officer

Ownership: Direct

2026-05-12Sale

Owner: Fordyce, Marshall

Title: PRESIDENT AND CEO

Shares: 18,500

Price/Share: $36.86

Value: $681,910.00

Shares Owned: 216,744

Relationship: Director,Officer

Ownership: Direct

2026-04-14Sale

Owner: Fordyce, Marshall

Title: PRESIDENT AND CEO

Shares: 22,951

Price/Share: $44.58

Value: $1,023,155.58

Shares Owned: 235,244

Relationship: Director,Officer

Ownership: Direct

2026-02-23Sale

Owner: Brenner, Robert

Title: Chief Medical Officer

Shares: 2,151

Price/Share: $41.98

Value: $90,298.98

Shares Owned: 50,947

Relationship: Officer

Ownership: Direct

2026-02-23Sale

Owner: Skelton, Laurence Matthew

Title: Chief Commercial Officer

Shares: 1,582

Price/Share: $41.98

Value: $66,412.36

Shares Owned: 64,218

Relationship: Officer

Ownership: Direct

Filed Date	Owner	Relationship	Title	Ownership	Purchase/Sale	No. Shares	Price Per Share	Value	Shares Owned	Document Type
2026-06-23	Fordyce, Marshall	Director,Officer	PRESIDENT AND CEO	Direct	Sale	18,500	38.18	$706,330.00	198,244	4
2026-05-12	Fordyce, Marshall	Director,Officer	PRESIDENT AND CEO	Direct	Sale	18,500	36.86	$681,910.00	216,744	4
2026-04-14	Fordyce, Marshall	Director,Officer	PRESIDENT AND CEO	Direct	Sale	22,951	44.58	$1,023,155.58	235,244	4
2026-02-23	Brenner, Robert	Officer	Chief Medical Officer	Direct	Sale	2,151	41.98	$90,298.98	50,947	4
2026-02-23	Skelton, Laurence Matthew	Officer	Chief Commercial Officer	Direct	Sale	1,582	41.98	$66,412.36	64,218	4
2026-02-23	Young, Joseph R	Officer	SVP, FINANCE, CHIEF ACCT OFFCR	Direct	Sale	3,117	41.98	$130,851.66	64,722	4
2026-02-23	Fordyce, Marshall	Director,Officer	PRESIDENT AND CEO	Direct	Sale	16,925	41.98	$710,511.50	257,163	4
2026-02-23	Turner, William D.	Officer	Chief Regulatory Officer	Direct	Sale	2,187	41.98	$91,810.26	45,313	4
2026-02-23	Johnson, David Lee	Officer	Chief Operating Officer	Direct	Sale	2,579	41.98	$108,266.42	45,727	4
2026-02-23	Grant, Sean	Officer	CHIEF FINANCIAL OFFICER	Direct	Sale	4,949	41.98	$207,759.02	114,181	4
2025-12-15	Turner, William D.	Officer	Chief Regulatory Officer	Direct	Sale	10,000	50.08	$500,800.00	22,500	4
2025-12-11	Enright, Patrick G	Director	-	Direct	Purchase	5,882	42.50	$249,985.00	5,882	4
2025-12-08	Turner, William D.	Officer	Chief Regulatory Officer	Direct	Sale	10,000	45.31	$453,100.00	22,500	4
2025-12-03	Turner, William D.	Officer	Chief Regulatory Officer	Direct	Sale	10,000	40.00	$400,000.00	22,500	4
2025-11-21	Carter, Jason S	Officer	Chief Legal Officer	Direct	Sale	3,864	27.82	$107,496.48	49,136	4
2025-11-11	Young, Joseph R	Officer	SVP, FINANCE, CHIEF ACCT OFFCR	Direct	Sale	15,000	29.06	$435,900.00	47,839	4
2025-06-24	Enright, Patrick G	Director	-	Indirect	Purchase	40,607	22.35	$907,566.45	3,596,593	4
2025-02-26	Fordyce, Marshall	Director,Officer	PRESIDENT AND CEO	Direct	Sale	9,075	27.94	$253,555.50	204,665	4
2025-01-08	Fordyce, Marshall	Director,Officer	PRESIDENT AND CEO	Direct	Sale	17,500	41.85	$732,375.00	143,603	4
2024-12-18	Fordyce, Marshall	Director,Officer	PRESIDENT AND CEO	Direct	Sale	17,500	43.01	$752,675.00	85,942	4
2024-12-11	Fordyce, Marshall	Director,Officer	PRESIDENT AND CEO	Direct	Sale	17,500	47.26	$827,050.00	85,942	4
2024-11-25	Fordyce, Marshall	Director,Officer	PRESIDENT AND CEO	Direct	Sale	19,375	48.36	$936,975.00	85,942	4
2024-11-13	Fordyce, Marshall	Director,Officer	PRESIDENT AND CEO	Direct	Sale	30,625	49.84	$1,526,350.00	85,942	4
2024-10-28	Seidenberg, Beth C	Director	-	Direct	Sale	15,000	48.78	$731,700.00	131,553	4
2024-10-23	Fordyce, Marshall	Director,Officer	PRESIDENT AND CEO	Direct	Sale	19,375	41.03	$794,956.25	307,972	4
2024-10-09	Fordyce, Marshall	Director,Officer	PRESIDENT AND CEO	Direct	Sale	15,625	38.46	$600,937.50	307,972	4
2024-09-25	Fordyce, Marshall	Director,Officer	PRESIDENT AND CEO	Direct	Sale	23,125	46.19	$1,068,143.75	307,972	4
2024-09-19	Seidenberg, Beth C	Director	-	Direct	Sale	13,823	42.31	$584,851.13	146,553	4
2024-09-11	Fordyce, Marshall	Director,Officer	PRESIDENT AND CEO	Direct	Sale	15,625	37.54	$586,562.50	307,972	4
2024-08-28	Fordyce, Marshall	Director,Officer	PRESIDENT AND CEO	Direct	Sale	30,320	37.17	$1,126,994.40	307,972	4
2024-08-21	Fordyce, Marshall	Director,Officer	PRESIDENT AND CEO	Direct	Sale	14,471	39.76	$575,366.96	322,667	4
2024-08-14	Fordyce, Marshall	Director,Officer	PRESIDENT AND CEO	Direct	Sale	15,625	37.56	$586,875.00	337,138	4
2024-05-16	Young, Joseph R	Officer	SVP, FINANCE, CHIEF ACCT OFFCR	Direct	Sale	20,651	42.62	$880,145.62	51,206	4
2024-04-10	Young, Joseph R	Officer	SVP, FINANCE, CHIEF ACCT OFFCR	Direct	Sale	5,714	40.00	$228,560.00	53,171	4
2024-04-03	Grant, Sean	Officer	CHIEF FINANCIAL OFFICER	Direct	Sale	99,828	39.02	$3,895,288.56	66,337	4
2024-03-25	Katabi, Maha	Director	-	Indirect	Sale	340,000	40.50	$13,770,000.00	2,793,987	4
2024-01-30	Katabi, Maha	Director	-	Indirect	Purchase	161,290	31.00	$4,999,990.00	3,628,446	4
2024-01-10	Commodore, Capital Lp	TenPercentOwner	-	Indirect	Sale	1,050,000	18.00	$18,900,000.00	4,400,000	4
2023-08-21	Fordyce, Marshall	Director,Officer	President and CEO	Direct	Sale	5,210	16.66	$86,798.60	243,361	4
2023-08-21	Lin, Celia	Officer	Chief Medical Officer	Direct	Sale	1,490	16.65	$24,808.50	11,010	4
2023-08-21	Curley, Joanne	Officer	Chief Development Officer	Direct	Sale	1,490	16.66	$24,823.40	26,962	4
Additional insider transactions are for subscribers only. Unlock the complete Form 4 filing history Start 7-day free trial

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Institutional Ownership

No data available for chart

2026-03-31

94.34%

Inst. Shares: 67,429,968

Shares Outstanding: 71,476,595

2025-12-31

106.10%

Inst. Shares: 68,154,776

Shares Outstanding: 64,233,814

2025-09-30

95.44%

Inst. Shares: 60,933,781

Shares Outstanding: 63,847,055

2025-06-30

91.84%

Inst. Shares: 58,581,523

Shares Outstanding: 63,789,303

2025-03-31

87.63%

Inst. Shares: 55,798,214

Shares Outstanding: 63,671,558

Date	Institutional Shares Owned	Shares Outstanding	Institutional Ownership %
2026-03-31	67,429,968	71,476,595	94.34%
2025-12-31	68,154,776	64,233,814	106.10%
2025-09-30	60,933,781	63,847,055	95.44%
2025-06-30	58,581,523	63,789,303	91.84%
2025-03-31	55,798,214	63,671,558	87.63%
2024-12-31	55,502,669	55,326,680	100.32%
2024-09-30	47,685,314	54,898,297	86.86%
2024-06-30	48,793,202	54,728,552	89.15%
2024-03-31	48,368,846	50,971,933	94.89%
2023-12-31	40,932,153	42,707,072	95.84%
2023-09-30	38,831,047	44,363,419	87.53%
2023-06-30	37,828,158	44,269,772	85.45%
Additional institutional holders are for subscribers only. Unlock the complete Form 13F ownership history Start 7-day free trial

Vera Therapeutics, Inc. (VERA) — SEC Financial Statements & Analysis

Vera Therapeutics, Inc. (VERA) is a pharmaceutical preparations company, incorporated in DE. Vera Therapeutics, Inc. trades on Nasdaq as: VERA. Based on its latest SEC filing (Form 10-Q, period ending 2026-06-30), Vera Therapeutics, Inc. reported a Debt-to-Equity ratio of 0.31x, a Price-to-Book (P/B) ratio of 7.56x (TTM), at a market cap of $3.08B. Figures below are sourced from SEC EDGAR, as-filed.

Debt To Equity: 0.31x
P/B TTM: 7.56x
Market Cap: $3.08B

Data as of 2026-06-30 · Source: SEC EDGAR

Frequently Asked Questions

What industry is Vera Therapeutics, Inc. in?

Vera Therapeutics, Inc. (VERA) operates in the Pharmaceutical Preparations industry.

What is VERA's market cap?

Vera Therapeutics, Inc. (VERA) has a market capitalization of $3.08B as of 2026-06-30.

What exchange does VERA trade on?

Vera Therapeutics, Inc. (VERA) trades on the Nasdaq.

Where is Vera Therapeutics, Inc. incorporated?

Vera Therapeutics, Inc. is incorporated in DE.